Contraindications: Not suitable for individuals with pre-existing cardiac arrhythmia, structural heart disease, unmanaged hypertension, hyperthyroidism, or history of adrenergic hypersensitivity. Pregnancy and lactation are absolute contraindications. Women competing in tested federations should verify detection windows relevant to their governing body before beginning any pre-contest protocol.
Side Effects: Sympathomimetic effects including elevated resting heart rate, peripheral vasodilation, fine-motor tremor, and diaphoresis are dose-dependent and typically most pronounced in the initial escalation days. Muscle cramping — linked to intracellular electrolyte shifts in skeletal muscle — and appetite suppression may occur; the latter is generally advantageous during a caloric-restricted final prep but should not be mistaken for dietary sufficiency.
Monitoring: Resting heart rate measured before rising each morning serves as the primary escalation gate throughout the finisher block. Serum electrolytes — particularly potassium and magnesium — should be assessed at the midpoint of the protocol via a standard clinical panel. Blood pressure monitoring via validated home sphygmomanometer is recommended at minimum twice weekly during weeks of dose escalation.
PCT: Clenbuterol is not androgenic and does not suppress the hypothalamic-pituitary-gonadal axis; no classical post-cycle therapy targeting gonadotropin recovery is required following its use as a standalone compound. When stacked within an AAS-inclusive pre-contest protocol, PCT requirements are governed by the androgenic compounds in that stack, not by Clenbuterol itself.
Lab Tested
